Symbols

KURA

Kura Oncology·NASDAQ

--(--)

KURA fundamentals

KURA Q4 2025 Earnings

Kura Oncology (KURA) released its earnings on Mar 5, 2026: revenue was 15.20M (YoY -71.78%), missed estimates; EPS was -0.92 (YoY -318.18%), missed estimates.

Revenue / YoY

15.20M

-71.78%

EPS / YoY

-0.92

-318.18%

Report date

Mar 5, 2026

KURA Earnings Call Summary for Q4,2025

Q4 2025 Revenue Beat: $2.1 million in KOMZIFTI sales, with strong payer coverage and step-edit policy adoption.
$7B TAM Ambition: Targeting frontline AML and combination therapies to expand beyond $350M relapsed/refractory market.
Pipeline Momentum: Phase I data shows ziftomenib + 7+3 achieving 80% CR rates; darlafarnib combo trials in solid tumors advancing.
Financial Strength: $667M cash balance supports AML program through 2028; 2026 collaboration revenue guidance: $45-$55M.

Earnings

EPS

Revenue

Revenue & Expenses

KURA has released its 2025 Q4 earnings report, with revenue of 17.34M, reflecting a YoY change of -67.83%, and net profit of -81.00M, showing a YoY change of -321.50%. The Sankey diagram below clearly presents KURA's revenue sources and cost distribution.

Key Indicators

Kura Oncology (KURA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Kura Oncology (KURA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Kura Oncology (KURA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Kura Oncology (KURA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown